

Processing your request...
Dialog Index Results

Your select statement is 'S NORWAY (10N) (TYPE OR
SEROTYPE)(10N)4(15N)PNEUMO?' in databases ALLMEDPH.

☒ Select All☒ Clear Selections

<u>File</u>	<u>Database Name</u>	<u>Hits</u>
<input type="checkbox"/> 349:	<u>WIPO/PCT Patents Fulltext</u>	5
<input type="checkbox"/> 351:	<u>Derwent World Patents Index</u>	1
<input type="checkbox"/> 484:	<u>Periodical Abstracts PlusText(TM)</u>	1
<input type="checkbox"/> 654:	<u>U.S. Patents Fulltext (1976-present)</u>	8

There are 4 databases matching your statement 'S NORWAY (10N) (TYPE OR
SEROTYPE)(10N)4(15N)PNEUMO?'.

© 2004 Dialog, a Thomson business

2/3,AB/6 (Item 1 from file: 484)

03356836 **Supplier Number:** 97267479 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Increase in pneumococcal bacteraemia in Sweden

Giesecke, Johan; Fredlund, Hans

Lancet (GLAN) , v349 n9053 , p 699-700

Mar 8, 1997

ISSN: 0140-6736 **Journal Code:** GLAN

Document Type: Feature

Language: English **Record Type:** Fulltext; Abstract

Word Count: 632

Abstract:

Giesecke and Fredlund indicate that there is evidence of a developing "epidemic" of bacteremic pneumococcal infections in Sweden just like i Norway and the UK, yet there does not seem to be either an increase or decrease among children vaccinated against Hemophilus influenzae type

Periodical Abs Plustext (Dialog® File 484): (c) 2004 ProQuest. All rights reserved.

2/3,AB/7 (Item 1 from file: 654)

5529289

Utility

Immunogenic pneumococcal protein and vaccine compositions thereof

Inventor:Koenig, Scott, Rockville, MD

Johnson, Leslie S., Germantown, MD

Adamou, John E., Germantown, MD

Assignee: MedImmune, Inc. (02), Gaithersburg, MD

Examiner: Graser, Jennifer E. (Art Unit: 165)

Combined Principal Attorneys: Olstein, Elliot M.; Grant, Alan J.

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 6689369	A	20040210	US 2001844124	20010427
Priority				US 2001844124	20010427

Abstract:

The present invention relates to novel immunogenic polypeptides, a therapeutically active fragments thereof, and vaccines, and vaccine compositions, for the prevention and treatment of streptococcal infection, especially by Streptococcus pneumoniae. The invention als relates to antibodies against the disclosed polypeptides, as well as methods of disease prevention and/or treatment.

US Pat.Full. (Dialog® File 654): (c) Format only 2004 The Dialog Corp. All rights reserved.

7

2/3,AB/9 (Item 3 from file: 654)

0005486376

Derwent Accession: 2000-452129

Vaccine compositions comprising streptococcus pneumoniae
polypeptides having selected structural motifs

Inventor:Johnson, Leslie, INV

Adamou, John, INV

	Publication Number	Kind	Date	Application Number	Filing Date
	-----	--	-----	-----	-----
Main Patent	US 20040001836	A1	20040101	US 2003412850	20030414
Division	US 6582706			US 99468656	19991221
Provisional				US 60-113048	19981221
Priority				US 99468656	19991221
				US 60-113048	19981221
				US 2003412850	20030414

Abstract:

A vaccine composition is disclosed that comprises polypeptides and fragments of polypeptides containing histidine triad residues or coiled-coil regions, some of which polypeptides or fragments lie bet 80 and 680 residues in length. Also disclosed are processes for preventing infection caused by S. pneumoniae comprising administerin vaccine compositions.

US Pat.Full. (Dialog® File 654): (c) Format only 2004 The Dialog Corp. All rights reserved.

2/3,AB/11 (Item 5 from file: 654)

0005304841

Derwent Accession: 1999-601465

Derivatives of choline binding proteins for vaccines

Inventor:Theresa Wizemann, INV

Scott Koenig, INV

Leslie Johnson, INV

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20030138447	A1	20030724	US 2002254995	20020925
Division	US 6503511			US 99286981	19990406
Provisional				US 60-85743	19980515
Provisional				US 60-80878	19980407
Priority				US 99286981	19990406
				US 60-85743	19980515
				US 60-80878	19980407
				US 2002254995	20020925

Abstract:

The present invention provides bacterial immunogenic agents for administration to humans and non-human animals to stimulate an immun response. It particularly relates to the vaccination of mammalian sp with pneumococcal derived polypeptides that include an alpha helix b exclude a choline binding region as a mechanism for stimulating production of antibodies that protect the vaccine recipient against infection by pathogenic bacterial species. In another aspect the invention provides antibodies against such proteins and protein comp that may be used as diagnostits and/or as protective/treatment agen for pathogenic bacterial species.

US Pat.Full. (Dialog® File 654): (c) Format only 2004 The Dialog Corp. All rights reserved.

2/3,AB/14 (Item 8 from file: 654)

4806698

Derwent Accession: 1999-601465

Utility

CERTIFICATE OF CORRECTION

C/ Derivatives of choline binding proteins for vaccines

Inventor:Wizemann, Theresa M., Potomac, MD

Koenig, Scott, Rockville, MD

Johnson, Leslie S., Germantown, MD

Assignee: MedImmune, Inc. (02), Gaithersburg, MD

MedImmune Inc (Code: 40463)

Examiner: Minnifield, Nita (Art Unit: 165)

Combined Principal Attorneys: Olstein, Elliot M.; Grant, Alan J.

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 6503511	A	20030107	US 99286981	19990406
Priority				US 99286981	19990406

Abstract:

The present invention provides bacterial immunogenic agents for administration to humans and non-human animals to stimulate an immun response. It particularly relates to the vaccination of mammalian sp with pneumococcal derived polypeptides that include an alpha helix b exclude a choline binding region as a mechanism for stimulating production of antibodies that protect the vaccine recipient against infection by pathogenic bacterial species. In another aspect the invention provides antibodies against such proteins and protein comp that may be used as diagnostics and/or as protective/treatment agen for pathogenic bacterial species.

Document type: C CERTIFICATE OF CORRECTION

US Pat.Full. (Dialog® File 654): (c) Format only 2004 The Dialog Corp. All rights reserved.

© 2004 Dialog, a Thomson business